Lv1
90 积分 2025-07-31 加入
Teprotumumab-Related Adverse Events in Thyroid Eye Disease
5小时前
已完结
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment
1个月前
已完结
Re: Shah et al.: Teprotumumab-related adverse events in thyroid eye disease: a multicenter study (Ophthalmology. 2023 Oct 16:S0161-6420(23)00760-1)
1个月前
已完结
Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study
2个月前
已完结
Long-term tocilizumab therapy in patients with corticosteroid-resistant active moderate-to-severe thyroid eye disease
3个月前
已完结
The role of teprotumumab in chronic, clinically active thyroid eye disease
3个月前
已完结
Teprotumumab for Asymmetric Thyroid Eye Disease
3个月前
已关闭
Teprotumumab vs Intravenous Methylprednisolone for Thyroid Eye Disease
4个月前
已完结
Rundle’s Curve: A Useful Construct That Does Not Fit All
5个月前
已关闭
Spontaneous Improvement of Untreated Mild Graves' Ophthalmopathy: Rundle's Curve Revisited
5个月前
已完结
皖公网安备34019202002308
